Medtronic saw 8.7% year over year growth in the third quarter of fiscal year 2026, according to financial results posted Feb. 17.
Five things to know:
1. Medtronic saw $9 billion in global revenue, and $4.5 billion in U.S. sales.
2. Neuroscience sales were $2.6 billion, a 2.5% increase year over year.
3. Cranial and spinal technologies saw 4.8% year over year growth with $1.3 billion. Specialty therapies and neuromodulation saw year-over-year growth of 1.9% and 5.8%, respectively.
4. Medical Surgical business revenue was $2.2 billion, a 4.9% increase year over year, and cardiovascular sales were $3.5 billion, a 13.8% jump. Diabetes revenue was $796 million, a 14.8% year over year increase.
5. Medtronic maintained its fiscal year 2026 guidance and expects 5.5% full-year growth.
